Table 3 Novel antibody-drug conjugates for acute myeloid leukemia
Drug name | Target | Payload | Linker | Development stage |
|---|---|---|---|---|
Vadastuximab talirine (SGN-CD33A) | CD33 | PBD dimer | Dipeptide linker (protease-cleavable) | Phase III |
IMGN779 | CD33 | DGN462 | Disulfide linker | Phase I |
AVE9633 (huMy9–6-DM4) | CD33 | DM4 | Disulfide linker | Phase I (terminated) |
IMGN632 | CD123 | IGN | Dipeptide linker (protease-cleavable) | Phase I |
SGN-CD123A | CD123 | PBD dimer | Dipeptide linker (protease-cleavable) | Phase I (terminated) |
CLT030 | CLL-1 | IQB | Dipeptide linker (protease-cleavable) | Preclinical |
Anti-CLL-1 ADC | CLL-1 | PBD dimer | Disulfide linker | Preclinical |